152 related articles for article (PubMed ID: 7160667)
21. [Prognostic and therapeutic significance of bone marrow biopsy in multiple myeloma. Analysis of 31 stage II A and III A patients].
Paule B; Quillard J; Medicis P; Bourgeois P; Grossin M; Bisson M; Kahn MF
Rev Rhum Mal Osteoartic; 1988 Jan; 55(1):27-32. PubMed ID: 3353673
[TBL] [Abstract][Full Text] [Related]
22. [Multiple myeloma of bones. Retrospective study of prognostic factors based on a series of 243 patients].
Bataille R; Donadio D; Morlock G; Rosenberg F; Blotman F; Sany J; Simon L; Izarn P; Serre H
Rev Rhum Mal Osteoartic; 1979 Feb; 46(2):77-83. PubMed ID: 432517
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic factors affecting survival in multiple myeloma].
Tornóczky J; Tóth A; Sziládi E; Hoffmann E; Liszátz M
Orv Hetil; 1990 Aug; 131(31):1679-84. PubMed ID: 2205822
[TBL] [Abstract][Full Text] [Related]
24. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
25. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system.
Durie BG
Eur J Cancer; 2006 Jul; 42(11):1539-43. PubMed ID: 16777405
[TBL] [Abstract][Full Text] [Related]
26. Multiple myeloma in the region of Bursa, Turkey: a retrospective analysis.
Ozkalemkaş F; Ali R; Tunali A; Ozkocaman V; Ozyardimci C; Ozçelik T
J Environ Pathol Toxicol Oncol; 1996; 15(2-4):267-70. PubMed ID: 9216819
[TBL] [Abstract][Full Text] [Related]
27. [BUN, Bence Jones protein, and chromosomal aberrations predict survival in multiple myeloma].
Okada K; Oguchi N; Shinohara K; Tamura N; Ishii K; Noguchi Y; Hayashi S; Yamamoto H; Takeichi M; Fujimoto H; Shirota T; Hayashi T
Rinsho Ketsueki; 1997 Dec; 38(12):1254-62. PubMed ID: 9455144
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic factors of multiple myeloma].
Paule B
Ann Med Interne (Paris); 1997; 148(8):534-41. PubMed ID: 9538400
[TBL] [Abstract][Full Text] [Related]
29. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
Alexandrakis MG; Passam FH; Kyriakou DS; Christophoridou AV; Perisinakis K; Hatzivasili A; Foudoulakis A; Castanas E
Am J Hematol; 2004 Feb; 75(2):101-6. PubMed ID: 14755377
[TBL] [Abstract][Full Text] [Related]
30. [Clinical importance of the paraprotein index in multiple myeloma].
Papajík T; Bacovský J; Zadrazil J; Budíková M; Faltýnek L; Scudla V
Vnitr Lek; 1994 Aug; 40(8):502-5. PubMed ID: 7941436
[TBL] [Abstract][Full Text] [Related]
31. DNA-image cytometry and clinical staging systems in multiple myeloma.
Kropff M; Leo E; Steinfurth G; Esselborn H; Adler CP; Böcking A
Anticancer Res; 1994; 14(5B):2183-8. PubMed ID: 7840520
[TBL] [Abstract][Full Text] [Related]
32. Anion gap among patients of multiple myeloma and normal individuals.
Mansoor S; Siddiqui I; Adil S; Nabi Kakepoto G; Fatmi Z; Ghani F
Clin Biochem; 2007 Feb; 40(3-4):226-9. PubMed ID: 17156769
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of a morphologic staging method (myeloma progression score) in multiple myeloma].
Pasqualetti P; Casale R; Collacciani A; Colantonio D
Medicina (Firenze); 1989; 9(3):280-2. PubMed ID: 2615598
[TBL] [Abstract][Full Text] [Related]
34. Critical considerations on a comparative study of two staging systems for multiple myeloma.
Merlini G; Jayakar D
Nouv Rev Fr Hematol (1978); 1984; 26(6):397-400. PubMed ID: 6527945
[TBL] [Abstract][Full Text] [Related]
35. [Proposal of a new staging system using scoring of multiple myeloma].
Pasqualetti P; Collacciani A; Casale R; Colantonio D
Medicina (Firenze); 1989; 9(4):410-3. PubMed ID: 2634228
[TBL] [Abstract][Full Text] [Related]
36. [Clinical features and survival of Chilean patients with multiple myeloma].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2007 Sep; 135(9):1111-7. PubMed ID: 18064364
[TBL] [Abstract][Full Text] [Related]
37. Critical study of staging in multiple myeloma.
Pennec Y; Mottier D; Youinou P; Asselain B; Chavance M; Le Goff P; Le Prise PY; Miossec P; Le Menn G
Scand J Haematol; 1983 Feb; 30(2):183-90. PubMed ID: 6860419
[TBL] [Abstract][Full Text] [Related]
38. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
Mihou D; Katodritou E; Zervas K
Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
[TBL] [Abstract][Full Text] [Related]
39. Prognostic variables and clinical staging in multiple myeloma.
Cavo M; Galieni P; Zuffa E; Baccarani M; Gobbi M; Tura S
Blood; 1989 Oct; 74(5):1774-80. PubMed ID: 2790201
[TBL] [Abstract][Full Text] [Related]
40. [Serum thymidine kinase in multiple myeloma: II. Relation to disease activity and stage].
Scudla V; Papajík T; Bacovský J; Budíková M; Klímová D
Vnitr Lek; 1994 Mar; 40(3):157-62. PubMed ID: 8184567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
